Compounding, quality and safety
Compounded medicines are prepared by pharmacies and are not FDA-approved products. Grey-market peptides sold online have no oversight at all. Documented problems include incorrect potency, wrong or unlisted substances, contamination and non-sterility, and the FDA has restricted certain peptides from compounding on safety grounds.
The difference between FDA-approved, compounded and grey-market peptides, what the FDA's compounding categories mean, and the documented risks of unregulated.
Same molecule name on the label does not mean the same thing in the vial.
Key takeaways
- Compounded is not the same as approved; neither is it the same as grey market.
- The FDA maintains categories governing which bulk substances may be compounded.
- Independent testing has repeatedly found mislabelled and impure grey-market products.
- Non-sterile injectable products carry infection risks that are entirely preventable.
Three supply routes
Approved product. Manufactured under regulatory oversight, with batch testing, a reviewed label and adverse event reporting.
Compounded preparation. Made by a 503A pharmacy for an individual patient or a 503B outsourcing facility. Legitimate in defined circumstances, such as an allergy to an excipient or a needed formulation change. Not FDA-approved, and not reviewed for safety and effectiveness.
Grey market. Sold online as 'research use only'. No identity, purity, potency or sterility assurance, and no accountable prescriber.
What the FDA compounding categories mean
The FDA evaluates bulk drug substances that pharmacies want to use in compounding and sorts them into categories. Some may be used while under evaluation; others are placed in a category indicating significant safety risk, which effectively removes them from legitimate compounding.
Several peptides popular online have been assessed under this process. Because the lists are updated, the current FDA page is the only reliable reference, and it is linked in the sources below.
The 2026 compounding changes, and what they did not change
At its meeting on 23-24 July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding six peptides - BPC-157, KPV, TB-500, MOTS-c, epitalon and Semax - to the 503A bulk drug substances list, and declined to recommend emideltide (delta sleep-inducing peptide).
On 28 October 2026, before that rulemaking was finished, HHS announced an interim enforcement discretion policy, published in the Federal Register on 30 October (document 2026-22192). The FDA will not take action against a licensed pharmacist or physician who compounds one of those six peptides for an individual patient with a valid prescription, provided the product contains only that one peptide, uses the permitted route, is made from an ingredient supplied by an FDA-registered establishment with a certificate of analysis, and serious side effects are reported to MedWatch. Large outsourcing facilities, 'research chemical' sellers and dietary supplements are not covered.
Three points matter for reading that news accurately. The policy is interim: HHS says it may revise or withdraw it if safety or quality problems appear. It is not approval: the notice states that compounded drugs are not FDA-approved and that the FDA does not review their safety or effectiveness. And it says nothing new about whether these compounds work in people; the human evidence for each is unchanged.
The notice, the committee materials and the current 503A bulks list are all linked in the sources below - check them directly rather than relying on any summary, including this one.
What goes wrong in practice
Documented problems with unregulated injectable products include:
- Potency far above or below the stated amount.
- A different compound than the one on the label.
- Bacterial contamination and endotoxin in non-sterile preparations.
- Residual solvents and manufacturing impurities.
- Counterfeit packaging imitating approved brands.
Questions worth asking a clinician
If a peptide has been suggested to you, these are reasonable questions to raise with a licensed prescriber - not with a seller.
- Is this an FDA-approved product, a compounded preparation, or neither?
- What is the approved indication, and is my use inside or outside it?
- What human trial evidence exists for my situation specifically?
- What are the known adverse effects and how would we monitor for them?
- What would we do instead if this were not available?
Frequently asked questions
Why do compounded versions exist if approved products are available?
Legitimate reasons include allergy to an ingredient, a required dose form that is not manufactured, or a documented shortage. Cost alone is not a clinical justification, and regulators have acted against compounding driven purely by demand.
Are third-party test certificates from sellers reliable?
They are not independently verifiable, can be reused across batches, and typically test identity rather than sterility. They are not equivalent to regulated manufacturing oversight.
Where can I check the current status of a specific peptide?
The FDA's human drug compounding pages, the 503A bulk substances list, the Pharmacy Compounding Advisory Committee materials and Drugs@FDA are the authoritative sources. All are linked in the sources below.
Did the 2026 changes make peptides like BPC-157 legal?
Partly, and narrowly. Since 28 October 2026 a licensed pharmacist or physician can compound BPC-157 and five other peptides for an individual patient with a prescription, under the conditions of an interim HHS policy, without FDA enforcement action. That is not FDA approval, it is not evidence the compounds work, and it does not cover 'research use only' products sold online, which are still not legal to sell for use in people.
Related on Beiing
- Peptide status tracker - Which column each peptide is in today.
- Approved peptide medicines - What approval certifies.
- Research and experimental peptides - The other end of the supply spectrum.
- How Beiing rates peptide evidence - The five evidence levels used across this section.
- Peptides & Human Biology - The hub for every page in this section.
- Editorial Standards - How our content is researched and reviewed.
Sources
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Federal Register document 2026-22192, docket HHS-OASH-2026-0496) - U.S. Department of Health and Human Services, via the Federal Register
- FDA - Human Drug Compounding - U.S. Food and Drug Administration
- FDA - Bulk Drug Substances Used in Compounding Under Section 503A - U.S. Food and Drug Administration
- FDA - Pharmacy Compounding Advisory Committee meetings and materials - U.S. Food and Drug Administration
- FDA - FDA's concerns with unapproved GLP-1 drugs used for weight loss - U.S. Food and Drug Administration
- MedWatch: report a side effect or product problem - U.S. Food and Drug Administration
- FDA winds down GLP-1 compounding policies (1 April 2025) - TechTarget Pharma Life Sciences
- Drugs@FDA - approved drug products and labels - U.S. Food and Drug Administration
Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.
Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.